Oxford BioMedica R&D Day

RNS Number : 5943O

Oxford Biomedica PLC

01 July 2010

 



OXFORD BIOMEDICA PLC

("Oxford BioMedica" or the "Company")

Research and Development Day

Oxford, UK - 1 July 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy company, will hold an R&D day for analysts and investors today in London.

The meeting will focus on the Company's Parkinson's disease and ocular disorders programmes and the applicability of its LentiVector^® technology. Presentations will be made by members of Oxford BioMedica's Senior Management Team and also by Key Opinion Leaders associated with the Company, namely Professor Stephane Palfi, Principal Investigator of Oxford BioMedica's ProSavin trial, and Peter Francis, Associate Professor, Co-Director, Oregon Retinal Degeneration Center.

A copy of the presentation will be available following the meeting from Oxford BioMedica's website: http://www.oxfordbiomedica.co.uk. The company will not be disclosing any new material information.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Andrew Wood, Chief Financial Officer	Tel: [phone]
Media/Financial Enquiries: Emma Thompson/ Rob Newman/ Ben Simons M:Communications	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica^®

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector^®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

MSCLLFSDRRIIVII